Rationale for RAS mutation-tailored therapies

Steven K. Montalvo, Lianbo Li, Kenneth D. Westover

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalFuture Oncology
Issue number3
StatePublished - Feb 2017


  • GTPase
  • RAS
  • cancer
  • isoforms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Rationale for RAS mutation-tailored therapies'. Together they form a unique fingerprint.

Cite this